Dysregulation in brain-derived neurotrophic factor (BDNF)/full-length TrkB (TrkB-TK+) signaling is implicated in promoting neurodegeneration in Alzheimer's disease (AD). BDNF/TrkB-TK+ signaling can be modulated by the presence of truncated TrkB isoforms (TrkB-TK-, TrkB-Shc). All TrkB isoforms are encoded by different alternative transcripts. In this study, we assessed if expression of the three main TrkB alternative transcripts, TrkB-TK+, TrkB-TK-, and TrkB-Shc are altered in AD. Using a cohort of control and AD brains (n=29), we surveyed the hippocampus, temporal cortex, occipital cortex, and cerebellum and found specific increases in TrkB-Shc, a neuron-specific transcript, in the AD hippocampus. No significant changes were detected in TrkB-TK+ and TrkB-TK-transcript levels in AD in any brain region examined. Corresponding changes in truncated TrkB protein levels were found in the hippocampus, although a significant increase in the temporal cortex was also observed. Our findings suggested that neuron-specific changes in TrkB may be occurring in AD; thus, we determined whether TrkB-Shc expression could be modulated by amyloid beta 1-42 (Aβ 42). We found increased TrkB-Shc mRNA levels in differentiated SHSY5Y neuronal cell-lines exposed to fibril-containing Aβ 42 preparations. When we assessed the cellular impact of increased TrkB-Shc, we found co-localization between TrkB-Shc and TrkB-TK+. Interestingly, TrkB-Shc overexpression selectively attenuated BDNF/TrkB-TK+-mediated signaling via the mitogen-activated protein kinase kinase (MEK) pathway, but not the protein kinase B pathway. In AD, MEK signaling is increased in vulnerable neurons and linked to abnormal phosphorylation of cytoskeletal proteins. Altogether, our findings suggest that elevated TrkB-Shc expression in AD may function as a compensatory response in neurons in AD to promote survival. (Knusel et al., 1991 , Ghosh et al., 1994 , McAllister et al., 1995 , Itami et al., 2000 , Alonso et al., 2002 , Lu et al., 2008 , Schindowski et al., 2008 ). The neurotrophic effects of BDNF are mediated by the tropomyosin receptor kinase B (TrkB), a membrane-bound receptor tyrosine kinase which can activate various cell signaling pathways linked to growth, differentiation, and survival (Patapoutian and Reichardt, 2001, Bartkowska et al., 2010).
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Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases in humans and is characterized by amyloid-E (AE) deposition, tau neurofibrillary tangles, and neuronal loss. Deficits in brain-derived neurotrophic factor (BDNF) signaling have been proposed to facilitate the progressive neurodegeneration in AD (Schindowski et al., 2008) . The growth promoting actions of BDNF are critical for survival and plasticity of a variety of neurons throughout the brain. Moreover, BDNF has been demonstrated to be vital for neuronal growth, differentiation, axonal guidance, behavior, cognition and memory formation; and hippocampal neurogenesis (Knusel et al., 1991 , Ghosh et al., 1994 , McAllister et al., 1995 , Itami et al., 2000 , Alonso et al., 2002 , Lu et al., 2008 , Schindowski et al., 2008 ). The neurotrophic effects of BDNF are mediated by the tropomyosin receptor kinase B (TrkB), a membrane-bound receptor tyrosine kinase which can activate various cell signaling pathways linked to growth, differentiation, and survival (Patapoutian and Reichardt, 2001, Bartkowska et al., 2010) .
The TrkB gene is expressed as multiple alternative splice transcripts that give rise to different protein isoforms (Luberg et al., 2010) . Three major TrkB transcripts/isoforms are expressed in the human brain (Stoilov et al., 2002 , Luberg et al., 2010 . The high affinity, full-length (TrkB-TK+) TrkB receptor is encoded by 24 exons and is expressed primarily by neurons. It contains a catalytic tyrosine kinase domain that is necessary for activating second messenger signaling via the MEK, AKT, and PLCJ pathways to mediate the neurotrophic effects of BDNF (Klein et al., 1991 , Stoilov et al., 2002 , Luberg et al., 2010 (Fig. 1) . The Cterminal truncated TrkB receptors include TrkB-TK-and TrkB-Shc. TrkB-TK-is encoded by 16 exons and is expressed primarily by glia, although expression in neurons has also been reported (Stoilov et al., 2002 , Ohira and Hayashi, 2003 , Ohira et al., 2005a , Ohira et al., 2005b , Luberg et al., 2010 . Unlike TrkB-TK+ transcripts which do not have exon 16, TrkB-TK-transcripts include exon 16. Exon 16 encodes a stop codon and this leads to the Section Editor: Cellular and Molecular Neuroscience: L. Kaczmarek 5 generation of a short isoform-specific C-terminal domain that lacks the catalytic tyrosine kinase domain (Klein et al., 1990) (Fig. 1) . Thus, TrkB-TK-may inhibit neurotrophin signaling by sequestering or trapping neurotrophins to prevent binding and signal transduction via TrkB-TK+ homodimers (Biffo et al., 1995 , Fryer et al., 1997 , or act in a manner similar to "antigen presenting" receptors by binding to BDNF and presenting it to nearby cells expressing TrkB-TK+ (Beck et al., 1993 , Frisen et al., 1993 . Alternatively, TrkB-TK-has been demonstrated in vitro to act as a dominant-negative receptor when coexpressed in the same cell type by forming inactive heterodimers with TrkB-TK+ to prevent neurotrophin signaling (Eide et al., 1996 , Ninkina et al., 1996 . The other major C-terminal truncated TrkB receptor isoform, TrkB-Shc, differs from TrkB-TK-in that it is expressed only by neurons (Stoilov et al., 2002) . It contains a sarc homology binding site (Shc) in the juxtamembrane domain similar to TrkB-TK+, however, TrkB-Shc transcripts include exon 19 which is not present in TrkB-TK+ transcripts. Exon 19 also contains a stop codon that leads to the translation of a unique truncated C-terminus which also lacks the tyrosine kinase domain (Stoilov et al., 2002) (Fig. 1) . Thus, TrkB-Shc may also act as a negative regulator of TrkB-TK+ as it is able to dimerize with TrkB-TK+ but is unable to signal via tyrosine kinase (Stoilov et al., 2002) .
At present, studies examining changes in TrkB mRNA and protein expression in AD are incomplete and conflicting changes in TrkB-TK+ and TrkB-TK-expression have been reported. In AD brains, reductions in TrkB-TK+ protein in neurons have mostly been found in the hippocampus and the temporal and frontal cortices (Allen et al., 1999 , Ferrer et al., 1999 . Others have reported no loss of TrkB immunnoreactivity in AD parietal cortex, however this was using an antibody to TrkB-TK- (Savaskan et al., 2000) . Moreover, previous studies of TrkB expression in the hippocampus of AD brains have only examined TrkB-TK+ Section Editor: Cellular and Molecular Neuroscience: L. Kaczmarek 6 and TrkB-TK-protein expression by immunohistochemistry and western blotting (Connor et al., 1996 , Ferrer et al., 1999 .
Interestingly, while the existence of TrkB-Shc has been known for some time, its role in AD has yet to be described. Considering that TrkB-Shc has been characterized to be expressed only in neurons (Stoilov et al., 2002) , and that neurotrophin signaling is decreased in neurons in AD, it is important to establish what role TrkB-Shc plays in AD development and progression.
In the present study, we took a quantitative approach to specifically measure the expression levels of each of the three major TrkB alternative splice variants (TrkB-TK+, TrkB-TK-, and TrkB-Shc) in the hippocampus (a region heavily impacted in AD), temporal cortex (a region also affected in AD), occipital cortex (an area affected late in AD), and cerebellum (a region relatively spared in AD) of AD brains. Considering that TrkB-Shc is neuronal specific, we also determined if changes in its expression could be modulated in an amyloidogenic environment and whether increased TrkB-Shc has a functional impact on BDNF/TrkB-TK+ signaling in a neuronal setting. 
Experimental Procedures

Brain cohorts
Two brain cohorts were used in this study. For the hippocampus and cerebellum, the brain cohort comprised n=6 controls and n=6 AD cases (Sydney Brain Bank and New South Wales Tissue Resource Centre, Sydney, Australia). For the temporal and occipital cortices, the brain cohort comprised n=8 controls and n=9 AD cases (this was generously provided by Professor Glenda Halliday). All cases were longitudinally evaluated to autopsy, and data and brain collected for research purposes as approved by Institutional Human Ethics Committees. AD brains were clinically and pathologically defined using NIA-Reagan criteria as described previously (NIA, 1997 , Gregory et al., 2006 . All AD cases had Braak neuritic stages V and VI. Demographic data for the cohorts are detailed in Table 1 . Control and AD cases were matched for age and gender where possible. The diagnostic groups did not differ according to age, brain pH, or postmortem interval (PMI) (all p0.12). Samples were taken from the same anatomical regions of the brain, as previously described Cell culture and treatments SHSY5Y cells were obtained from the American Type Culture Collection (ATCC) and grown at 37°C in a 5% CO 2 atmosphere. For continuous culture, SHSY5Y cells were cultured in RPMI media containing 10% (v/v) FBS supplemented with glutamax (2 mM).
For experiments, SHSY5Y cells were differentiated for 9 days using all-trans retinoic acid (ATRA:10 PM) which was added to the culture medium. During differentiation, the differentiation media (growth media + ATRA) was refreshed every 3 days. For transfections, differentiated SHSY5Y cells were transfected using OptiMEM medium and Lipofectamine Table 2 . Primers were designed to span an intron/exon boundary to avoid amplification of possible genomic DNA. PCR cycling conditions were:
95°C for 1 min, 45 cycles of 95°C for 30 seconds, primer specific annealing temperature for 30 seconds (Table 2) , and 72°C for 30 seconds. Control reactions with no template were included which produced no signal. Melt curve analysis and agarose gel electrophoresis were performed to confirm production of a single product. Changes in gene expression levels were determined by normalizing mRNA levels of the gene of interest to the mRNA level of the housekeeping gene, E-actin using the 2 -''CT method (Livak and Schmittgen, 2001 ). E-Actin did not vary with treatment and there was no difference in E-actin expression between control and AD cases in any of the brain regions examined (all p>0.06) (Fig. S1A ). For details on housekeeping gene selection, please refer to the Supplemental Results.
AE 42 preparation
Section Editor: Cellular and Molecular Neuroscience: L. Kaczmarek 9 AE 42 monomers, oligomers, and fibrils were prepared using a modified protocol from Ryan et al. (Ryan et al., 2010) . Lyophilized AE 42 peptides were reconstituted in DMSO to a working concentration of 1 mM. For experiments, 1 PM was used as the final concentration. The volume required for each experiment was aliquoted for preparation. For monomers, aliquots were sonicated for 10 min and briefly vortexed. For oligomer preparations, after sonication, monomers were diluted 1:10 using PBS+0.05% SDS, vortexed for 30 seconds, and incubated at 4 ƕ C for 40 h. For fibril preparations, after sonication, monomers were diluted 1:10 using PBS, vortexed for 30 seconds, and incubated at 37 ƕ C for 40 h.
Atomic Force Microscopy (AFM)
AE 42 samples (20 Pl) prepared as described above were pipetted onto the surface of freshly cleaved 1 x 1 cm mica. Samples were incubated on the mica surface for 30 min to allow for sufficient adsorption of the AE 42 samples and then washed by exchanging the sample solution (six times) with nanopure water. The AE 42 -coated mica surface was then air dried and mounted on the AFM sample stage and static mode force measurements were performed using an Asylum Research MFP-3D AFM (Santa Barbara, CA) as previously described (Higgins et al., 2006) . Images were captured using the Asylum Research AFM IGOR Pro software (Wavemetrics, Lake Oswego, OR).
Immunofluorescence staining and fluorescence microscopy SHSY5Y cells were seeded in 24-well plates containing sterile 12 × 12 mm glass coverslips (density of: 6×104) and differentiated for 9 days as described above. Cells were transfected with overexpression plasmids [pcDNA3.1-TrkB-Shc-myc and pcDNA3.1-TrkB-TK+-EGFP ProLong® Gold antifade reagent with DAPI (Molecular probes). Images were obtained using a Nikon ECLIPSE RE2000-E micorscope (Nikon, Japan).
Western blotting
Tissues (10mg) and cells were harvested for total protein using homogenization buffer (human tissue) (Wong et al., 2009) or RIPA buffer (cells) supplemented with protease inhibitors (2 mM AEBSF, 0.015 mM aprotinin, 0.038 mM leupeptin, 0.030 mM pepstatin A, 0.028 mM E-64, 0.08 mM bestatin) (Sigma) and phosphatase inhibitors (Pierce). Protein concentrations were determined by the bicinchoninic acid method. Samples (including AE preparations) were mixed with 5 × SDS loading buffer (containing E-mercaptoethanol), boiled at 95ºC for 5 min, and separated on 10% or 13% SDS-PAGE gels (13% was used for AE preparations). Proteins were transferred onto nitrocellulose membranes and blocked using 5% (w/v) non-fat milk, 0.1% (v/v) Tween-20 in TBS (TBST) at room temperature for 1 h. For membranes containing AE samples, membranes were boiled in PBS for 5 min prior to blocking to expose epitopes in oligomers and fibrils (Takahashi et al., 2004) . Membranes were incubated with primary antibodies: WO2 (1:500 dilution), which recognizes the AE peptide; TrkB (1:3000) (BD Biosciences); phospho-TrkB (1:5000) (Epitomics); AKT1 1 1
(1:5000), phospho-AKT1 (1:5000), ERK1/2 (1:20000), phospho-ERK1/2 (1:20000) (Cell Signaling), myc (1:5000) (Invitrogen), and E-actin (1:10000) (Sigma). Membranes were washed 3 x 10 min with TBST and incubated with mouse peroxidase-conjugated affinity purified secondary antibody for 1 h (Dako). After further washing, bound antibodies were incubated with enhanced chemiluminescence reagent (Millipore) and visualized by autoradiography. Bands were quantitated by densitometry using Image J (version 1.37v) (National Institutes of Health USA). The brightness/contrast of images was adjusted using Adobe Photoshop CS (version 8).
Statistical analysis
All cell culture experiments were from 3 replicate cultures representative of 3-6 independent experiments. Data are presented as mean + standard error of the mean (SEM). Outliers were determined and removed from subsequent analyses using the Grubb's test or if data points were greater or less than two standard deviations from the mean (qPCR: Hippocampus: 
Results
TrkB-Shc transcript levels are increased in the hippocampus of AD brains
We found highly significant increases in TrkB-Shc mRNA levels in the hippocampus of AD brains compared to controls (t=-4.03, df=8, p=0.004) ( Fig. 2A) . A trend towards increased TrkB-TK-mRNA levels was observed in the AD hippocampus compared to controls (t=-2.10, df=8, p=0.07). No significant change in hippocampal TrkB-TK+ mRNA levels could be detected between control and AD cases (t=-1.26, df=9, p=0.24).
To determine whether the increase observed in TrkB-Shc mRNA levels are related to the location and severity of tissue pathology, we assessed whether changes in TrkB-Shc mRNA expression are altered in the temporal cortex (a region affected after the hippocampus) as well as the occipital cortex and cerebellum (two regions less affected in AD). Interestingly, we found no significant change in TrkB-Shc mRNA levels in any of the three brain regions examined between control and AD cases (all p>0.17) (Fig. 2B-D) .
Moreover, no significant differences were observed in TrkB-TK-(all p>0.16) or TrkB-TK+ (all p>0.20) mRNA levels between control and AD cases.
TrkB protein expression in AD
TrkB immunoreactive bands migrating at ~140kDa (corresponding to full-length TrkB) and ~90kDa (corresponding to truncated TrkB) were detected in all control and AD samples in all four brain regions examined (Fig. 3A) . The ~90kDa band appeared large and diffuse in all samples from all four brain regions. This is likely because the TrkB-TK-and TrkB-Shc isoforms are similar in size and both migrate at ~90kDa. We observed significant increases in the ~90kDa TrkB protein in the hippocampus (t=-2.67, df=9, p=0.03) and temporal cortex (t=-3.60, df=15, p=0.003) of AD brains compared to controls ( difference in expression of the ~90kDa protein was observed between AD and controls in the occipital cortex (U=16, Z=1.68, p=0.09) and cerebellum (t=-1.61, df=10, p=0.14) ( Fig. 3D and E).
Interestingly, expression of the ~140kDa band corresponding to the TrkB-TK+ protein was significantly increased in the hippocampus of AD brains compared to controls (U=4, Z=-2.24, p=0.02) (Fig. 3B) . No significant differences were observed in expression of the ~140kDa protein in the temporal cortex, occipital cortex, and cerebellum between AD and control brains ( Fig. 3C-E ) (all p>0.09).
GFAP mRNA levels in AD
Elevations in TrkB-TK-mRNA and truncated TrkB protein levels in AD have previously been associated with increased astrocyte numbers in the diseased state (Duguid et al., 1989 , Muramori et al., 1998 . To determine if the increases in TrkB-TK-mRNA (trend only) and truncated TrkB protein levels we observed are associated with changes in astrocytes in AD,
we measured GFAP mRNA levels in the same brain regions where TrkB alternative transcript levels were assessed. We found elevated levels of GFAP mRNA in the hippocampus (U=5, Z=-2.08, p=0.04), temporal cortex (t=-3.47, df=15, p=0.003), and occipital cortex (U=9, Z=-2.60, p=0.009) of AD brains compared to controls ( Fig. S2A-C) .
No significant change in GFAP transcript levels was observed in the AD cerebellum (t=-0.35, df=8, p=0.73) (Fig. S2D ). When we examined whether changes in TrkB-TK-mRNA and truncated protein levels were correlated with changes in GFAP mRNA levels, we found that 
AE 42
We prepared different structural forms of AE using a modified protocol from Ryan et al. (Ryan et al., 2010) . The presence of AE monomers, oligomers, and fibrils were confirmed by western blotting (using WO2 antibody which recognizes the AE peptide) and found to be consistent with AE preparations previously reported by us and by others (Garzon and Fahnestock, 2007 , Ryan et al., 2010 (Fig. 4A) . The monomeric AE preparation (lane 1) contained mostly monomers (~4 kDa) but it also contained small oligomers (12-22 kDa). We did not detect any large oligomers or fibrils. The oligomeric AE preparation (lane 2) contained monomers, small and large oligomers (40-70 kDa). The fibrillar AE preparation (lane 3) contained monomers, small oligomers, some large oligomers, and fibrils (>250 kDa).
To extend our characterization of the AE preparations utilized in this study, in addition to western blotting, we also visualized the three different AE preparations using AFM (Fig. 4B) . The monomer preparation contained monomers and small aggregates of AE . These are likely to correspond to the small oligomers observed in western blot analysis ( Fig. 4A lane 1) . Also similar to our findings by western blotting, we observed varying sizes of AE oligomers and fibrils in their respective preparations by AFM. In the oligomer preparation, we found evidence of some oligomers aggregating into fibrils ( Fig. 4B and S3A ).
However, it was in the fibril preparation that most fibrillar AE species were observed ( 4B and S3B), including protofibrils which can reach up to ~100 nm in length (Arimon et al., 2005) as indicated by the black arrows in Figure S3B .
Fibrillar AE 42 increases TrkB-Shc transcript levels in the differentiated SHSY5Y neuronal cell-line
The increase in TrkB-Shc mRNA levels in the AD hippocampus but not in other brain regions examined suggests that factors specific to severe AD pathology may be modulating its expression. Thus, we determined whether TrkB alternative transcript expression in neuronal cell-lines can be modulated by different species of AE . We found a modest but significant increase in TrkB-Shc mRNA levels (t=-2.33, df=15, p=0.03) in differentiated SHSY5Y neuronal cells treated with preparations of AE containing fibrils but not with preparations containing monomers or oligomers (all p>0.36) (Fig. 5) . No significant changes in TrkB-TK-(all p>0.07) and TrkB-TK+ (all p>0.17) mRNA levels were observed in any of the treatment conditions.
TrkB-Shc co-localizes with TrkB-TK+
TrkB-Shc has previously been shown to co-localize with TrkB-TK+ in non-neuronal cells (Stoilov et al., 2002) . To determine whether TrkB-Shc can co-colocalize with TrkB-TK+ in neuronal cells, we co-overexpressed TrkB-Shc and GFP-tagged TrkB-TK+ in differentiated SHSY5Y cells. We observed co-localisation between TrkB-TK+ and TrkB-Shc (Fig. 6 ). Both
TrkB-Shc and TrkB-TK+ showed cytoplasmic and plasma membrane localisation (Fig. 6A , B, and D). Expression of both isoforms could also be observed in neurites. TrkB-TK+ was found to localise mostly around the soma, whereas TrkB-Shc was observed to distribute into more distal regions of neurites. Interestingly, TrkB-TK+ and to a lesser extent, TrkB-Shc,
were found to be highly concentrated in the endoplasmic reticulum. No expression of either isoform could be detected in the nucleus (Fig. 6A-D both empty vector and TrkB-Shc transfected cells, treatment of cells with 25ng of BDNF had little effect on pAKT:AKT, pERK1:ERK1, and pERK2:ERK2 expression ratios and levels appeared similar to the vehicle treatment condition. This finding suggests that our experimental system was likely to have been saturated at 25ng BDNF. This is likely as treatment with 25ng BDNF had a more potent effect at increasing the pTrkB:TrkB-TK+ expression ratio than in the empty vector (t=-3.03, df=6, p=0.02).
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Discussion
In this study, we report several novel findings: First, we found elevated levels of the neuronspecific truncated TrkB alternative transcript, TrkB-Shc in the hippocampus but not in the temporal cortex, occipital cortex, and cerebellum of AD brains. Second, we found that exposure of differentiated SHSY5Y neuronal cell-lines to AE preparations containing fibrils increased TrkB-Shc transcript levels. Finally, increasing TrkB-Shc protein expression in differentiated SHSY5Y cells attenuated BDNF-stimulated-TrkB-TK+ mediated second messenger signaling via the MEK pathway.
TrkB-Shc and AD
To date, TrkB-Shc expression in AD brain tissues has yet to be described. Considering that TrkB-Shc expression is neuron-specific (Stoilov et al., 2002) , it is surprising that this gap in the knowledgebase exists. Here, we show that TrkB-Shc transcripts are elevated in the AD hippocampus, but not in the temporal cortex, occipital cortex, or cerebellum; suggesting that increases in this TrkB alternative splice transcript is occurring in brain regions that are most severely affected in the diseased state and that the observed increase may likely be influenced by the neuronal cell population. In support of this, we found that TrkB-Shc mRNA levels in differentiated neuronal cell-lines can be increased by exposure to preparations of AE containing fibrils. Interestingly, AE preparations that did not contain fibrillar AE species had no significant effect on TrkB-Shc transcript levels.
At present, it is widely accepted that soluble oligomers are the more neurotoxic of the AE species, however, evidence also indicates that the neurotoxicity of AE requires its aggregation in the fibrillar form, particularly in the form of protofibrils (Walsh et al., 1999 , Serpell, 2000 . By AFM, we were able to detect various sizes of fibrils in the fibril AE preparations, including protofibrils which can be ~100 nm in length. Our images of the fibril preparations are very similar to those reported by Arimon et al. (2005) . Here, the authors found that protofibrils co-exist with larger fibrils and are able to incorporate into larger fibrillar structures. In our preparations, we observed similar finidings. In the oligomer preparations, while we observed evidence of some oligomers aggregating into fibrils, the predominant form of AE were globular oligomers of various sizes. Considering that AE fibrils are formed in the advanced stages of AD (Hoozemans et al., 2006) , that the hippocampus is the most impacted brain region, and that the CA1 subregion (the hippocampal region assessed in this study) is the most severely impacted subregion of the hippocampus in AD, altogether, our findings suggest that the selective increase in the TrkBShc alternative splice transcript in the AD hippocampus may be specific to severe, late stage pathology.
In the AD hippocampus, we found a trend towards an increase in TrkB-TK-mRNA levels but a significant elevation in truncated TrkB protein. Both TrkB-TK-and TrkB-Shc are predicted to migrate at similar molecular weights by denaturing SDS-PAGE, thus the increase in truncated TrkB protein is likely to reflect an increase in both TrkB-TK-and TrkBShc protein in the total hippocampal brain homogenate. While an increase in TrkB-TKmRNA levels and truncated TrkB protein are consistent with previous findings (Connor et al., 1996 , Ferrer et al., 1999 , it is in contrast to the lack of change we observed in differentiated SHSY5Y cells exposed to AE . TrkB-TK-is primarily expressed by astrocytes and previous studies have demonstrated that TrkB-TK-signaling via Rho-GTPase is critical in regulating astrocyte morphology (Ohira et al., 2005a) . Considering that astrocytes become activated when exposed to AE, the increase in TrkB-TK-in the AD hippocampus may be more reflective of increases in astrocytic TrkB-TK-expression as opposed to neuronal TrkB-TKexpression. This is likely as elevations in TrkB-TK-mRNA in AD have previously been found to be associated with reactive glia around senile plaques (Ferrer et al., 1999) . Moreover, when we surveyed GFAP mRNA levels in the hippocampus, temporal cortex, occipital cortex, and cerebellum, we found statistically significant elevations in all brain regions except for the cerebellum (a region relatively spared in AD).
Interestingly, while we found no significant changes in TrkB-TK+ mRNA levels in any of the four brain regions tested in AD compared to controls, we did find a significant increase in full-length TrkB protein in the hippocampus. This is consistent with previous findings which showed that both truncated and full-length TrkB immunoreactivity in the CA1 subregion of the hippocampus are elevated in AD compared to controls (Connor et al., 1996) .
Moreover, both truncated and full-length TrkB immunoreactivity detected by Connor et al. (1996) was found to localise to glial cells in association with senile plaques. Considering that astrocytes are also able to express TrkB-TK+ mRNA and full-length TrkB protein, our finding of elevated full-length TrkB protein in the AD hippocampus suggests that the increase is likely to be contributed by astrocytes.
In addition to the hippocampus, we also found a significant increase in truncated TrkB protein in the temporal cortex but not in the occipital cortex and cerebellum, consistent with previous findings (Allen et al., 1999) . The occipital cortex is affected less severely in AD and the cerebellum is relatively spared. If we take into consideration our finding of increased fulllength TrkB protein in the AD hippocampus, and findings of elevated GFAP mRNA levels in the hippocampus and temporal and occipital cortices, altogether, our findings may also be reflective of the progression of AD brain pathology ie. where pathology is most severe in the hippocampus>temporal cortex>occipital cortex>cerebellum.
Increased TrkB-Shc in AD: a negative regulator of BDNF/TrkB-TK+ signaling in AD?
The cellular response to BDNF is mediated by the full-length TrkB receptor, TrkB-TK+, and this can be modulated depending upon the relative ratios of the full-length TrkB to truncated TrkB receptors (Eide et al., 1996) . Changes in the relative levels of truncated TrkB receptors have been demonstrated to have a significant impact on neuronal BDNF availability and signaling. Co-expression of TrkB-TK-and TrkB-Shc in vitro have been found to have a dominant negative effect on TrkB-TK+ activity (Biffo et al., 1995 , Eide et al., 1996 , Ninkina et al., 1996 , Stoilov et al., 2002 . In accordance with these findings, we showed that TrkBShc can have a negative impact on human neuronal BDNF/TrkB-TK+ second messenger signaling via the MEK pathway where BDNF/TrkB-TK+ mediated phosphoryation of both ERK1 and ERK2 were reduced when exogenous TrkB-Shc was overexpressed. In contrast, little change was obseved in BDNF-stimulated phosphorylation of TrkB and AKT when TrkB-Shc was overexpressed. Unlike TrkB-TK+ signaling via the MEK pathway, which requires Shc adaptor proteins to bind to phosphorylated tyrosine residues on TrkB-TK+, signaling via AKT can also mediated via IRS1/2 (Yamada et al., 1997) . Thus, the lack of change in AKT phosphorylation upon TrkB-Shc overexpression may have resulted from alternative pathways being utilized upon BDNF stimulation.
Increased TrkB-Shc in AD: a compensatory response to promote cell survival in AD?
While there is evidence to support the notion that increased TrkB-Shc will negatively impact neuronal BDNF signaling (Biffo et al., 1995 , Eide et al., 1996 , Ninkina et al., 1996 , Stoilov et al., 2002 In our current study, we found that overexpression of TrkB-Shc in differentiated SHSY5Y cells could blunt BDNF/TrkB-TK+ stimulated MEK pathway signaling by attenuating pERK1/2:ERK1/2 ratios (a measure of ERK1/2 activity) but with little effect on pTrkB:TrkB-TK+ and pAKT:AKT ratios. In AD, MEK signaling and ERK1/2 phosphorylation is increased in vulnerable neurons, moreover, elevated MEK pathway activity is implicated in the abnormal phosphorylation of tau and neurofilament proteins (Perry et al., 1999) . Considering that BDNF/TrkB-TK+ mediated neuronal survival is more dependent upon AKT signaling than MEK signaling (Atwal et al., 2000) , our finding that elevated levels of TrkB-Shc in a neuronal setting can attenuate ERK1/2 phosphorylation following BDNF stimulation (but have no significant effect on phosphorylated AKT and TrkB at non-saturating levels) suggests that the increase in TrkB-Shc transcripts in the AD hippocampus and when cells are treated with fibrillar AE , may function as a compensatory mechanism in neurons in AD to promote survival. Further work is required to determine how TrkB-Shc is functioning in neurons in AD and whether changes in their expression at different stages of the disease process, in response to AE, or in response to other amyloidogenic factors may be protective or deleterious.
Conclusions
In this study, we demonstrated a novel increase in TrkB-Shc transcript levels in the AD (Luberg et al., 2010) and Wong et al. (Wong et al., 2011) . 
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